Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan [ibritumomab tiuxetan Y-90] Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial

Trial Profile

Efficacy and Safety of Subsequent Treatment With [90]Y-Ibritumomab Tiuxetan [ibritumomab tiuxetan Y-90] Versus no Further Treatment in Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma Having Achieved Partial or Complete Remission After First Line Chemotherapy. A Prospective, Multicenter, Randomized Phase III Clinical Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2013

At a glance

  • Drugs Ibritumomab tiuxetan (Primary)
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms FIT
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2010 Updated results will be presented at the 52nd American Society of Hematology annual meeting, according to a Spectrum Pharmaceuticals media release.
    • 06 Jul 2009 The US FDA has requested data from the FIT study to validate a subset of data from the supplemental Biologics License Application package for ibritumomab tiuxetan.
    • 28 Nov 2008 Data at a median 42 (2-77) months of follow-up in 409 patients presented at ASH 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top